(Q33414664)

26 July 2017

Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors (English)

1 reference

26 July 2017

phase I clinical trial

0 references

1 reference

6

Charles Erlichman

1 reference

26 July 2017

7

Steven R Alberts

1 reference

26 July 2017

4

George P Kim

1 reference

26 July 2017

2

Mitesh J Borad

1 reference

26 July 2017

5

Donald W Northfelt

1 reference

26 July 2017

Brian A Costello

1

1 reference

PubMed ID

24740268

26 July 2017

Yingwei Qi

series ordinal

3

1 reference

26 July 2017

18 April 2014

1 reference

Investigational New Drugs

26 July 2017

1 reference

26 July 2017

32

1 reference

26 July 2017

4

1 reference

26 July 2017

710-716

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-014-0096-3

26 July 2017

0 references

cites work

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0096-3

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0096-3

Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0096-3

Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0096-3

Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0096-3

In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0096-3

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0096-3

Phase II trial of m-AMSA in gallbladder and cholangiocarcinoma: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0096-3

Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0096-3

Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0096-3

Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report

21 January 2018

1 reference

12 December 2020

A phase II study of cisplatin in patients with biliary tract carcinoma

1 reference

12 December 2020

Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report

1 reference

12 December 2020

Single-dose etoposide in advanced pancreatic and biliary cancer, a phase II study

1 reference

12 December 2020

A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors

1 reference

12 December 2020

10.1007/S10637-014-0096-3

Identifiers

DOI

1 reference

PubMed ID

24740268

Dimensions Publication ID

26 July 2017

0 references

1 reference

PubMed ID

24740268